Literature DB >> 15521633

Human infectivity trait in Trypanosoma brucei: stability, heritability and relationship to sra expression.

C M R Turner1, S McLellan, L A G Lindergard, L Bisoni, A Tait, A MacLeod.   

Abstract

Some Trypanosoma brucei lines infect humans whereas others do not because the parasites are lysed by human serum. We have developed a robust, quantitative in vitro assay based on differential uptake of fluorescent dyes by live and dead trypanosomes to quantify the extent and kinetics of killing by human serum. This method has been used to discriminate between 3 classes of human serum resistance; sensitive, resistant and intermediate. TREU 927/4, the parasite used for the T. brucei genome project, is intermediate. The phenotype is expressed in both bloodstream and metacyclic forms, is stably expressed during chronic infections and on cyclical transmission through tsetse flies. Trypanosomes of intermediate phenotype are distinguished from sensitive populations of cells by the slower rate of lysis and by the potential to become fully resistant to killing by human serum as a result of selection or long-term serial passaging in mice, and to pass on full resistance phenotype to its progeny in a genetic cross. The sra gene has been shown previously to determine human serum resistance in T. brucei but screening for the presence and expression of this gene indicated that it is not responsible for the human serum resistance phenotype in the trypanosome lines that we have examined, indicating that an alternative mechanism for HSR exists in these stocks. Examination of the inheritance of the phenotype in F1 hybrids for both bloodstream and metacyclic stages from 2 genetic crosses demonstrated that the phenotype is co-inherited in both life-cycle stages in a manner consistent with being a Mendelian trait, determined by only one or a few genes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15521633     DOI: 10.1017/s0031182004005906

Source DB:  PubMed          Journal:  Parasitology        ISSN: 0031-1820            Impact factor:   3.234


  17 in total

1.  In vitro generation of human high-density-lipoprotein-resistant Trypanosoma brucei brucei.

Authors:  Sara D Faulkner; Monika W Oli; Rudo Kieft; Laura Cotlin; Justin Widener; April Shiflett; Michael J Cipriano; Sarah E Pacocha; Shanda R Birkeland; Stephen L Hajduk; Andrew G McArthur
Journal:  Eukaryot Cell       Date:  2006-08

Review 2.  The origins of the trypanosome genome strains Trypanosoma brucei brucei TREU 927, T. b. gambiense DAL 972, T. vivax Y486 and T. congolense IL3000.

Authors:  Wendy Gibson
Journal:  Parasit Vectors       Date:  2012-04-07       Impact factor: 3.876

3.  Mechanism of Trypanosoma brucei gambiense (group 1) resistance to human trypanosome lytic factor.

Authors:  Rudo Kieft; Paul Capewell; C Michael R Turner; Nicola J Veitch; Annette MacLeod; Stephen Hajduk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

4.  Phylogeography and taxonomy of Trypanosoma brucei.

Authors:  Oliver Balmer; Jon S Beadell; Wendy Gibson; Adalgisa Caccone
Journal:  PLoS Negl Trop Dis       Date:  2011-02-08

5.  Haptoglobin-hemoglobin receptor independent killing of African trypanosomes by human serum and trypanosome lytic factors.

Authors:  Whitney Bullard; Rudo Kieft; Paul Capewell; Nicola J Veitch; Annette Macleod; Stephen L Hajduk
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

6.  Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.

Authors:  Deuan C Jones; Irene Hallyburton; Laste Stojanovski; Kevin D Read; Julie A Frearson; Alan H Fairlamb
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

7.  Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1.

Authors:  Paul Capewell; Nicola J Veitch; C Michael R Turner; Jayne Raper; Matthew Berriman; Stephen L Hajduk; Annette MacLeod
Journal:  PLoS Negl Trop Dis       Date:  2011-09-06

8.  The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing.

Authors:  Rosario Diaz-Gonzalez; F Matthew Kuhlmann; Cristina Galan-Rodriguez; Luciana Madeira da Silva; Manuel Saldivia; Caitlin E Karver; Ana Rodriguez; Stephen M Beverley; Miguel Navarro; Michael P Pollastri
Journal:  PLoS Negl Trop Dis       Date:  2011-08-23

9.  Role of expression site switching in the development of resistance to human Trypanosome Lytic Factor-1 in Trypanosoma brucei brucei.

Authors:  Rudo Kieft; Natalie A Stephens; Paul Capewell; Annette MacLeod; Stephen L Hajduk
Journal:  Mol Biochem Parasitol       Date:  2011-12-29       Impact factor: 1.759

10.  Human and animal Trypanosomes in Côte d'Ivoire form a single breeding population.

Authors:  Paul Capewell; Anneli Cooper; Craig W Duffy; Andy Tait; C Michael R Turner; Wendy Gibson; Dieter Mehlitz; Annette Macleod
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.